Conjugate Vaccines Market by Type, Pathogen Type and End User - Global Industry Analysis & Forecast to 2027
Published On : June 2022 Pages : 170 Category: Pharma & Healthcare Report Code : HC064142
Conjugate Vaccines Market by Type (Multivalent Conjugate Vaccines, Monovalent Conjugate Vaccines) Pathogen Type (Viral Conjugate Vaccine, Bacterial Conjugate Vaccine, Combination (Viral and Bacterial) Conjugate Vaccine) End User (Adults, Pediatrics) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Conjugate vaccines are vaccines contains bacterial container polysaccharide and utilized for irresistible infections. It improves the immunogenic property of polysaccharide. Such kinds of immunizations are utilized to vaccinate babies and youngsters against obtrusive infection which are brought about by Streptococcus pneumonia, Neisseria meningitides, H. influenza, and Hib microorganisms. Conjugate Vaccines are right now being used for kids against pneumococcal bacterial diseases are made utilizing this method.
Drivers and Restraints
Expanding government activities across different nations, mechanical headways, improvement in antibody definition, and rising frequencies of irresistible ailments are main considerations expected to drive the development of the worldwide market over the forecast period. What's more, rising interest in innovative work exercises by key players working in the objective market, expanding interest for inoculation, and expanding inclination towards vaccination projects are some different components expected to further fuel development of the objective market over the forecast period.
Regional Insights
The market in North America is expected to dominate the worldwide market over the forecast period
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Pfizer Inc.
- Bharat Biotech International Limited
- Merck & Co., Inc.
- Sanofi Pasteur SA
- Novartis AG
- GlaxoSmithKline plc
- SutroVax, Inc.
- Taj Pharmaceuticals Limited
- Biological E. Limited
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Conjugate Vaccines Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Multivalent Conjugate Vaccines
o Monovalent Conjugate Vaccines
· Conjugate Vaccines Market, By Pathogen Type, Estimates and Forecast, 2017-2027 ($Million)
o Viral Conjugate Vaccine
o Bacterial Conjugate Vaccine
o Combination (Viral and Bacterial) Conjugate Vaccine
· Conjugate Vaccines Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Adults
o Pediatrics
· Conjugate Vaccines Market, By Key Players
o Pfizer Inc.
o Bharat Biotech International Limited
o Merck & Co., Inc.
o Sanofi Pasteur SA
o Novartis AG
o GlaxoSmithKline plc
o SutroVax, Inc.
o Taj Pharmaceuticals Limited
o Biological E. Limited
· Conjugate Vaccines Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Conjugate Vaccines Market, By Country
o U.S. Conjugate Vaccines Market
o Canada Conjugate Vaccines Market
o Mexico Conjugate Vaccines Market
o Europe
§ Europe Conjugate Vaccines Market, By Country
o Germany Conjugate Vaccines Market
o UK Conjugate Vaccines Market
o France Conjugate Vaccines Market
o Russia Conjugate Vaccines Market
o Italy Conjugate Vaccines Market
o Rest of Europe Conjugate Vaccines Market
o Asia-Pacific
§ Asia-Pacific Conjugate Vaccines Market, By Country
o China Conjugate Vaccines Market
o Japan Conjugate Vaccines Market
o South Korea Conjugate Vaccines Market
o India Conjugate Vaccines Market
o Southeast Asia Conjugate Vaccines Market
o Rest of Asia-Pacific Conjugate Vaccines Market
o South America
§ South America Conjugate Vaccines Market
o Brazil Conjugate Vaccines Market
o Argentina Conjugate Vaccines Market
o Columbia Conjugate Vaccines Market
o Rest of South America Conjugate Vaccines Market
o Middle East and Africa
§ Middle East and Africa Conjugate Vaccines Market
o Saudi Arabia Conjugate Vaccines Market
o UAE Conjugate Vaccines Market
o Egypt Conjugate Vaccines Market
o Nigeria Conjugate Vaccines Market
o South Africa Conjugate Vaccines Market
o Rest of MEA Conjugate Vaccines Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Conjugate Vaccines Market, By Type
5.1. Introduction
5.2. Global Conjugate Vaccines Revenue and Market Share by Type (2017-2027)
5.2.1. Global Conjugate Vaccines Revenue and Revenue Share by Type (2017-2027)
5.3. Multivalent Conjugate Vaccines
5.3.1. Global Multivalent Conjugate Vaccines Revenue and Growth Rate (2017-2027)
5.4. Monovalent Conjugate Vaccines
5.4.1. Global Monovalent Conjugate Vaccines Revenue and Growth Rate (2017-2027)
6. Conjugate Vaccines Market, By Pathogen Type
6.1. Introduction
6.2. Global Conjugate Vaccines Revenue and Market Share by Pathogen Type (2017-2027)
6.2.1. Global Conjugate Vaccines Revenue and Revenue Share by Pathogen Type (2017-2027)
6.3. Viral Conjugate Vaccine
6.3.1. Global Viral Conjugate Vaccine Revenue and Growth Rate (2017-2027)
6.4. Bacterial Conjugate Vaccine
6.4.1. Global Bacterial Conjugate Vaccine Revenue and Growth Rate (2017-2027)
6.5. Combination (Viral and Bacterial) Conjugate Vaccine
6.5.1. Global Combination (Viral and Bacterial) Conjugate Vaccine Revenue and Growth Rate (2017-2027)
7. Conjugate Vaccines Market, By End User
7.1. Introduction
7.2. Global Conjugate Vaccines Revenue and Market Share by End User (2017-2027)
7.2.1. Global Conjugate Vaccines Revenue and Revenue Share by End User (2017-2027)
7.3. Adults
7.3.1. Global Adults Revenue and Growth Rate (2017-2027)
7.4. Pediatrics
7.4.1. Global Pediatrics Revenue and Growth Rate (2017-2027)
8. Conjugate Vaccines Market, By Region
8.1. Introduction
8.2. Global Conjugate Vaccines Revenue and Market Share by Regions
8.2.1. Global Conjugate Vaccines Revenue by Regions (2017-2027)
8.3. North America Conjugate Vaccines by Countries
8.3.1. North America Conjugate Vaccines Revenue and Growth Rate (2017-2027)
8.3.2. North America Conjugate Vaccines Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Conjugate Vaccines by Countries
8.4.1. Europe Conjugate Vaccines Revenue and Growth Rate (2017-2027)
8.4.2. Europe Conjugate Vaccines Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Conjugate Vaccines by Countries
8.5.1. Asia-Pacific Conjugate Vaccines Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Conjugate Vaccines Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Conjugate Vaccines by Countries
8.6.1. South America Conjugate Vaccines Revenue and Growth Rate (2017-2027)
8.6.2. South America Conjugate Vaccines Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Conjugate Vaccines by Countries
8.7.1. Middle East and Africa Conjugate Vaccines Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Conjugate Vaccines Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Pfizer Inc.
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Bharat Biotech International Limited
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Merck & Co., Inc.
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Sanofi Pasteur SA
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. Novartis AG
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. GlaxoSmithKline plc
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. SutroVax, Inc.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
9.8. Taj Pharmaceuticals Limited
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Financial Overview
9.9. Biological E. Limited
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Financial Overview
10. Conjugate Vaccines Market Forecast (2017-2027)
10.1. Global Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Conjugate Vaccines Market Forecast by Regions (2017-2027)
10.2.1. North America Conjugate Vaccines Market Forecast (2017-2027)
10.2.1.1. United States Conjugate Vaccines Market Forecast (2017-2027)
10.2.1.2. Canada Conjugate Vaccines Market Forecast (2017-2027)
10.2.1.3. Mexico Conjugate Vaccines Market Forecast (2017-2027)
10.2.2. Europe Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.1. Germany Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.2. France Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.3. UK Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.4. Russia Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.5. Italy Conjugate Vaccines Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Conjugate Vaccines Market Forecast (2017-2027)
10.2.3. Asia-Pacific Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.1. China Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.2. Japan Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.3. Korea Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.4. India Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Conjugate Vaccines Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Conjugate Vaccines Market Forecast (2017-2027)
10.2.4. South America Conjugate Vaccines Market Forecast (2017-2027)
10.2.4.1. Brazil Conjugate Vaccines Market Forecast (2017-2027)
10.2.4.2. Argentina Conjugate Vaccines Market Forecast (2017-2027)
10.2.4.3. Columbia Conjugate Vaccines Market Forecast (2017-2027)
10.2.4.4. Rest of South America Conjugate Vaccines Market Forecast (2017-2027)
10.2.5. Middle East and Africa Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.3. Egypt Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.4. Nigeria Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.5. South Africa Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.6. Turkey Conjugate Vaccines Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Conjugate Vaccines Market Forecast (2017-2027)
10.3. Conjugate Vaccines Market Forecast by Type (2017-2027)
10.3.1. Conjugate Vaccines Forecast by Type (2017-2027)
10.3.2. Conjugate Vaccines Market Share Forecast by Type (2017-2027)
10.4. Conjugate Vaccines Market Forecast by Pathogen Type (2017-2027)
10.4.1. Conjugate Vaccines Forecast by Pathogen Type (2017-2027)
10.4.2. Conjugate Vaccines Market Share Forecast by Pathogen Type (2017-2027)
10.5. Conjugate Vaccines Market Forecast by End User (2017-2027)
10.5.1. Conjugate Vaccines Forecast by End User (2017-2027)
10.5.2. Conjugate Vaccines Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Conjugate Vaccines Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Conjugate Vaccines Revenue and Revenue Share by Type (2017-2018)
Figure Global Multivalent Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure Global Monovalent Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Table Global Conjugate Vaccines Revenue and Revenue Share by Pathogen Type (2017-2018)
Figure Global Viral Conjugate Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Bacterial Conjugate Vaccine Revenue and Growth Rate (2017-2018)
Figure Global Combination (Viral and Bacterial) Conjugate Vaccine Revenue and Growth Rate (2017-2018)
Table Global Conjugate Vaccines Revenue and Revenue Share by End User (2017-2018)
Figure Global Adults Revenue and Growth Rate (2017-2018)
Figure Global Pediatrics Revenue and Growth Rate (2017-2018)
Table Global Conjugate Vaccines Revenue by Regions (2017-2018)
Figure North America Conjugate Vaccines Growth Rate (2017-2018)
Figure North America Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure North America Conjugate Vaccines by Countries (2017-2018)
Figure North America Conjugate Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure United States Conjugate Vaccines Growth Rate (2017-2018)
Figure United States Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Conjugate Vaccines Growth Rate (2017-2018)
Figure Canada Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Conjugate Vaccines Growth Rate (2017-2018)
Figure Mexico Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Conjugate Vaccines Growth Rate (2017-2018)
Figure Europe Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure Europe Conjugate Vaccines by Countries (2017-2018)
Figure Europe Conjugate Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Germany Conjugate Vaccines Growth Rate (2017-2018)
Figure Germany Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Conjugate Vaccines Growth Rate (2017-2018)
Figure France Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Conjugate Vaccines Growth Rate (2017-2018)
Figure UK Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Conjugate Vaccines Growth Rate (2017-2018)
Figure Russia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Conjugate Vaccines Growth Rate (2017-2018)
Figure Italy Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Conjugate Vaccines Growth Rate (2017-2018)
Figure Rest of Europe Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Conjugate Vaccines Growth Rate (2017-2018)
Figure Asia-Pacific Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Conjugate Vaccines by Countries (2017-2018)
Figure Asia-Pacific Conjugate Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure China Conjugate Vaccines Growth Rate (2017-2018)
Figure China Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Conjugate Vaccines Growth Rate (2017-2018)
Figure Japan Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Conjugate Vaccines Growth Rate (2017-2018)
Figure Korea Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Conjugate Vaccines Growth Rate (2017-2018)
Figure India Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Conjugate Vaccines Growth Rate (2017-2018)
Figure Southeast Asia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Conjugate Vaccines Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Conjugate Vaccines Growth Rate (2017-2018)
Figure South America Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure South America Conjugate Vaccines by Countries (2017-2018)
Figure South America Conjugate Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Conjugate Vaccines Growth Rate (2017-2018)
Figure Brazil Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Conjugate Vaccines Growth Rate (2017-2018)
Figure Argentina Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Conjugate Vaccines Growth Rate (2017-2018)
Figure Columbia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Conjugate Vaccines Growth Rate (2017-2018)
Figure Rest of South America Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Conjugate Vaccines Growth Rate (2017-2018)
Figure Middle East and Africa Conjugate Vaccines Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Conjugate Vaccines by Countries (2017-2018)
Figure Middle East and Africa Conjugate Vaccines Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Conjugate Vaccines Growth Rate (2017-2018)
Figure Saudi Arabia Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Conjugate Vaccines Growth Rate (2017-2018)
Figure United Arab Emirates Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Conjugate Vaccines Growth Rate (2017-2018)
Figure Egypt Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Conjugate Vaccines Growth Rate (2017-2018)
Figure Nigeria Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Conjugate Vaccines Growth Rate (2017-2018)
Figure South Africa Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Conjugate Vaccines Growth Rate (2017-2018)
Figure Turkey Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Conjugate Vaccines Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer Inc. Conjugate Vaccines Financial Overview
Table Bharat Biotech International Limited Conjugate Vaccines Financial Overview
Table Merck & Co., Inc. Conjugate Vaccines Financial Overview
Table Sanofi Pasteur SA Conjugate Vaccines Financial Overview
Table Novartis AG Conjugate Vaccines Financial Overview
Table GlaxoSmithKline plc Conjugate Vaccines Financial Overview
Table SutroVax, Inc. Conjugate Vaccines Financial Overview
Table Taj Pharmaceuticals Limited Conjugate Vaccines Financial Overview
Table Biological E. Limited Conjugate Vaccines Financial Overview
Figure Global Conjugate Vaccines Revenue (Millions USD) and Growth Rate (2018-2025)
Table Conjugate Vaccines Market Forecast by Regions (2018-2025)
Figure North America Conjugate Vaccines Market Forecast (2018-2025)
Figure United States Conjugate Vaccines Market Forecast (2018-2025)
Figure Canada Conjugate Vaccines Market Forecast (2018-2025)
Figure Mexico Conjugate Vaccines Market Forecast (2018-2025)
Figure Europe Conjugate Vaccines Market Forecast (2018-2025)
Figure Germany Conjugate Vaccines Market Forecast (2018-2025)
Figure France Conjugate Vaccines Market Forecast (2018-2025)
Figure UK Conjugate Vaccines Market Forecast (2018-2025)
Figure Russia Conjugate Vaccines Market Forecast (2018-2025)
Figure Italy Conjugate Vaccines Market Forecast (2018-2025)
Figure Rest of Europe Conjugate Vaccines Market Forecast (2018-2025)
Figure Asia-Pacific Conjugate Vaccines Market Forecast (2018-2025)
Figure China Conjugate Vaccines Market Forecast (2018-2025)
Figure Japan Conjugate Vaccines Market Forecast (2018-2025)
Figure Korea Conjugate Vaccines Market Forecast (2018-2025)
Figure India Conjugate Vaccines Market Forecast (2018-2025)
Figure Southeast Asia Conjugate Vaccines Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Conjugate Vaccines Market Forecast (2018-2025)
Figure South America Conjugate Vaccines Market Forecast (2018-2025)
Figure Brazil Conjugate Vaccines Market Forecast (2018-2025)
Figure Argentina Conjugate Vaccines Market Forecast (2018-2025)
Figure Columbia Conjugate Vaccines Market Forecast (2018-2025)
Figure Rest of South America Conjugate Vaccines Market Forecast (2018-2025)
Figure Middle East and Africa Conjugate Vaccines Market Forecast (2018-2025)
Figure Saudi Arabia Conjugate Vaccines Market Forecast (2018-2025)
Figure United Arab Emirates Conjugate Vaccines Market Forecast (2018-2025)
Figure Egypt Conjugate Vaccines Market Forecast (2018-2025)
Figure Nigeria Conjugate Vaccines Market Forecast (2018-2025)
Figure South Africa Conjugate Vaccines Market Forecast (2018-2025)
Figure Turkey Conjugate Vaccines Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Conjugate Vaccines Market Forecast (2018-2025)
Figure Global Conjugate Vaccines Forecast by Type (2018-2025)
Figure Global Conjugate Vaccines Market Share Forecast by Type (2018-2025)
Figure Global Conjugate Vaccines Forecast by Type (2018-2025)
Figure Global Conjugate Vaccines Forecast by Pathogen Type (2018-2025)
Figure Global Conjugate Vaccines Market Share Forecast by Pathogen Type (2018-2025)
Figure Global Conjugate Vaccines Forecast by Pathogen Type (2018-2025)
Figure Global Conjugate Vaccines Forecast by End User (2018-2025)
Figure Global Conjugate Vaccines Market Share Forecast by End User (2018-2025)
Figure Global Conjugate Vaccines Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|